[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613465":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":79,"collaborators":20,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":83,"sex":89,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":20,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":20,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"Southern College of Optometry","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"TRYPTYR","EXPERIMENTAL","Participants who qualify for the study will be given TRYPTYR to determine if it is able to help alleviate symptoms associated with dry eye disease;",[13],"Drug: Acoltremon",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Acoltremon","Participants will be provided with Acoltremon or TRYPTYR to determine whether or not it is an effective medication to help alleviate symptoms associated with dry eye disease",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Chris Lievens, OD","CONTACT","901-722-3330","clievens@sco.edu",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"Quentin Franklin, BS, BA","6592064188","QuentinFranklin@uab.edu",[32,51,66],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Kannar Eye Care","RECRUITING","Pittsburg","Kansas","66762","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-94.70496,37.41088,{"lat":44,"lon":43},[47],{"name":48,"role":24,"phone":49,"phoneExt":20,"email":50},"Shane Kannarr, OD","6202351737","skannarr@kannarreyecare.com",{"facility":52,"status":34,"city":53,"state":54,"zip":55,"country":38,"countryCode":39,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Complete Eye Care of Medina","Medina","Minnesota","55340",{"type":41,"coordinates":57},[58,59],-93.58246,45.03524,{"lat":59,"lon":58},[62],{"name":63,"role":24,"phone":64,"phoneExt":20,"email":65},"Gina Wesley, OD","763-478-3505","leahlang@cecofmedina.com",{"facility":67,"status":34,"city":68,"state":69,"zip":70,"country":38,"countryCode":39,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"The Southern College of Optometry","Memphis","Tennessee","38104",{"type":41,"coordinates":72},[73,74],-90.04898,35.14953,{"lat":74,"lon":73},[77],{"name":23,"role":24,"phone":78,"phoneExt":20,"email":26},"9014815699",{"type":80,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100613465","phase-4-impact-of-tryptyr-on-a-patients-quality-of-life-and-ability-to-perform-work-100613465",false,"NCT07266948","Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work","Evaluating the Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work","TRYPTYR ADL","Inclusion Criteria:\n\n* Adults ≥18 years of age.\n* Have a history of DED for at least the past 6 months.\n* Are currently using Restasis as directed by their eye care provider for ≥1 month.\n* Participant intends to stop Restasis in the near future because and expressed dissatisfaction with effectiveness of Restasis in reducing dry eye symptoms..\n* Are symptomatic as determined with the Eye Dryness visual analog scale (VAS) (Score ≥50), SPEED (≥7), and have an abnormal Schirmer test score \\[≥2 to \\\u003C10 mm\u002F5 min\\]) at Screening\u002FBaseline.\n* Have corrected distance visual acuity of 20\u002F100 or better.\n* Willing to discontinue contact lens wear throughout the study.\n\nExclusion Criteria:\n\n* Have a systemic health condition that is known to alter tear film physiology (e.g., primary and secondary Sjögren's syndrome).\n* Have a history of ocular surgery within the past 12 months.\n* Have a history of severe ocular trauma, active ocular infection or inflammation that is not dry eye related.\n* Punctal plugs in place for \\\u003C 3 months and\u002For Lacrifill in place for \\> 5 months.\n* Have ever used Accutane or are currently using ocular medications (must washout from all dry eye medications\u002Ftreatments at least 1 week before entry, except for Restasis).\n* Use of artificial tears within 2 hours prior to the baseline visit or during the study.\n* Are pregnant or breast feeding.\n* Have had a physical meibomian gland treatment withing 1 month of enrollment.\n* Have a condition or be in a situation, which in the investigator's opinion, may put the participant at significant risk, may confound the results, or may significantly interfere with their study participation.","ALL","18 Years","75 Years",{"count":93,"type":94},40,"ESTIMATED","INTERVENTIONAL",[97],"PHASE4","This 1-month, 3-visit study will be conducted at the Southern College of Optometry (Memphis, TN), Kannarr Eye Care, LLC (Pittsburg, KS) and Complete Eye Care of Medina (Minneapolis, MN). Adults ≥18 years of age who have been diagnosed with DED for at least 6 months and who are currently symptomatic (Eye Dryness VAS Score ≥40) will be recruited. Subjects will have an abnormal Schirmer test of \\\u003C10 mm\u002F5 min. Subjects will also be required to score ≤70 on the IDEEL Quality of Life (QoL) Work domain to ensure that their DED symptoms are significantly impacting their ability to do work.9 Subjects will be required to have corrected distance visual acuity of 20\u002F32 (0.2 logMAR) or better.",[100,101,102],"Dry Eye","Eye Diseases","Eyes Dry Chronic","2025-11-25",{"date":105,"type":106},"2025-12-05","ACTUAL",{"date":108,"type":106},"2025-11-01",{"date":110,"type":94},"2026-03-01",{"name":5,"class":6},3]